PMID- 38479510
OWN - NLM
STAT- MEDLINE
DCOM- 20240415
LR  - 20240415
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
VI  - 354
DP  - 2024 Jun 1
TI  - Different dosage regimens of zuranolone in the treatment of major depressive 
      disorder: A meta-analysis of randomized controlled trials.
PG  - 206-215
LID - S0165-0327(24)00472-5 [pii]
LID - 10.1016/j.jad.2024.03.057 [doi]
AB  - OBJECTIVE: To investigate the efficacy and safety of different dosage regimens of 
      zuranolone in the treatment of patients with major depressive disorder (MDD). 
      METHODS: PubMed, Embase, The Cochrane Library and other databases were searched 
      from inception until July 2019. Randomized controlled trials (RCTs) related to 
      the efficacy and safety of zuranolone in the treatment of MDD were included. The 
      data were extracted independently by 2 investigators and assessed the study 
      quality by the Cochrane risk-of-bias tool. The primary outcome includes the 
      17-item HAMILTON total score (HAMD-17) and the incidence of adverse events (AEs). 
      RESULTS: Six high-quality RCTs with 1593 patients were finally included in our 
      analysis. Zuranolone group achieve a notable treatment effect at day15 in HAMD-17 
      compared with placebo group (MD = -2.69, 95 % CI: -4.45 to -0.94, P < 0.05). For 
      safety, no significant differences existed in the proportion of patients with AEs 
      between zuranolone with placebo (RR = 1.25, 95 % CI: 0.99 to 1.58, P = 0.06). 
      CONCLUSION: Zuranolone has a significant efficacy in improving depressive 
      symptoms in the short term and is positively correlated with the dosage 
      administered. However, the efficacy of zuranolone decreased significantly when 
      the time of administration was extended. Zuranolone demonstrated a controllable 
      safety issue. But adverse effects increased as the dose of zuranolone was 
      gradually increased to 50 mg.
CI  - Copyright (c) 2024 Elsevier B.V. All rights reserved.
FAU - Lian, Jinrong
AU  - Lian J
AD  - Department of Clinical Medicine, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu Province, China.
FAU - Lin, Zhimin
AU  - Lin Z
AD  - Department of Clinical Medicine, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu Province, China.
FAU - Li, Xiang
AU  - Li X
AD  - Department of Clinical Medicine, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu Province, China.
FAU - Chen, Gang
AU  - Chen G
AD  - Department of Clinical Medicine, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu Province, China. Electronic address: 
      nju_neurosurgery@163.com.
FAU - Wu, Depei
AU  - Wu D
AD  - Department of Clinical Medicine, The First Affiliated Hospital of Soochow 
      University, Suzhou, Jiangsu Province, China. Electronic address: 
      drwudepei@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240311
PL  - Netherlands
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
RN  - 7ZW49N180B (zuranolone)
RN  - 0 (Pyrazoles)
RN  - BXO86P3XXW (Pregnanolone)
SB  - IM
MH  - Humans
MH  - *Depressive Disorder, Major/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Pyrazoles/therapeutic use
MH  - Remission Induction
MH  - *Pregnanolone
OTO - NOTNLM
OT  - Efficacy
OT  - Major depressive disorder
OT  - Safety
OT  - Zuranolone
COIS- Declaration of competing interest The author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2024/03/14 00:43
MHDA- 2024/04/15 06:43
CRDT- 2024/03/13 20:26
PHST- 2023/11/06 00:00 [received]
PHST- 2024/02/06 00:00 [revised]
PHST- 2024/03/09 00:00 [accepted]
PHST- 2024/04/15 06:43 [medline]
PHST- 2024/03/14 00:43 [pubmed]
PHST- 2024/03/13 20:26 [entrez]
AID - S0165-0327(24)00472-5 [pii]
AID - 10.1016/j.jad.2024.03.057 [doi]
PST - ppublish
SO  - J Affect Disord. 2024 Jun 1;354:206-215. doi: 10.1016/j.jad.2024.03.057. Epub 
      2024 Mar 11.